Medicinova (MNOV) EBIT Margin (2012 - 2025)

Medicinova's (MNOV) quarterly EBIT Margin came in at 2037.97% in Q4 2025, up 25.67% on a QoQ basis from 2741.67% in Q3 2025.

Medicinova (MNOV) EBIT Margin (2012 - 2025) Analysis & Trends

Medicinova (MNOV) has 5 years of EBIT Margin data on file, last reported at 2037.97% in Q4 2025.

On a quarterly basis, EBIT Margin changed N/A year-over-year to 2037.97% in Q4 2025; TTM through Dec 2025 was 3242.47%, a N/A change from a year earlier, with the FY2025 full-year figure at 3242.47%, changed N/A from the prior year.
EBIT Margin for Q4 2025 stood at 2037.97%, up from 2741.67% in the prior quarter.
Over the last five years, EBIT Margin for MNOV reached as high as 5.04% in Q1 2021 and fell as low as 9605.17% in Q3 2021.
Historically, EBIT Margin has averaged 2864.07% across 3 years, with a median of 2358.93% in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Medicinova	64.48 Mn	64.48 Mn	4,754.00	-2,037.97%

Download Data